Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of FKC889 (Tecartus) in adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia
ChiCTR2300073872Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Peking University People's Hospital. Primary endpoint: Overall complete remission rate (CR + CRi) per independent review. Started Dec 2022; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2300073872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073872.